SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs2242480

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption

This study was designed for exploring the association of cytochrome P450 3A4 rs2242480 polymorphism with metabolism of sufentanil in Chinese patients receiving upper abdominal surgery,to provide evidence for genetic prediction of personalized medication.Methods:60 patients who prepared for elective upper abdominal surgery under general anesthesia were recruited into study. Liver enzyme inhibitor should be excluded in anesthesia. rs2242480 genotyping was carried out by direct sequencing. The blood samples were drawn before anesthesia,30 min and 45min after anesthesia respectively,used for plasma sufentanil concentration detection with high performance liquid chromatography-mass spectrometry (HPLC-MS). After surgery,the patients received patient-controlled intravenous sufentanil immediately. And postoperative pain at rest,sufentanil consumption,side effects and rescue analgesic requirements were recorded at the 6th,12th,24th hour. The plasma sufentanil concentration and PCA sufentanil consumption were analyzed to investigate the differences among rs2242480 three genotypes.

NCT02070614 Surgery Individuality

Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption.

Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption This study was designed for exploring the association of cytochrome P450 3A4 rs2242480 polymorphism with metabolism of sufentanil in Chinese patients receiving upper abdominal surgery,to provide evidence for genetic prediction of personalized medication.Methods:60 patients who prepared for elective upper abdominal surgery under general anesthesia were recruited into study.

rs2242480 genotyping was carried out by direct sequencing.

The plasma sufentanil concentration and PCA sufentanil consumption were analyzed to investigate the differences among rs2242480 three genotypes.

the correlation between rs2242480 polymorphism and sufentanil metabolism.

according to rs2242480 genotype and plasma concentration of sufentanil.

the single-dose sufentanil plasma concentration varies between participants, and the differences among 3 time-points is related with personal genotype.. relation between rs2242480 genotype and patient-controlled analgesia(PCA) consumption of sufentanil.

according to postoperative PCA sufentanil consumption and rs2242480 genotype.

relation between Visual Analogue Scale/Score(VAS) and rs2242480.

according to PCA VAS and rs2242480 genotype.

Participants were screened and stratified according to cytochrome P450 3A4 rs2242480 genotype: - 1/*1 Grouped by rs2242480 polymorphism, wild-type homozygote - 1/*1G Grouped by rs2242480 polymorphism,*1/*1G: mutant heterozygote - 1G/*1G Grouped by rs2242480 polymorphism,*1G/*1G: mutant homozygote

Primary Outcomes

Description: according to rs2242480 genotype and plasma concentration of sufentanil

Measure: the correlation between rs2242480 polymorphism and sufentanil metabolism

Time: 4 months

Secondary Outcomes

Description: the single-dose sufentanil plasma concentration varies between participants, and the differences among 3 time-points is related with personal genotype.

Measure: Variation of plasma concentration of sufentanil

Time: 4 months

Description: according to postoperative PCA sufentanil consumption and rs2242480 genotype

Measure: relation between rs2242480 genotype and patient-controlled analgesia(PCA) consumption of sufentanil

Time: 4 months

Description: according to PCA VAS and rs2242480 genotype

Measure: relation between Visual Analogue Scale/Score(VAS) and rs2242480

Time: 4 months


HPO Nodes